Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 3/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.33 |
| ▸ | NRP1 | O14786 | 2/20 | 0.30 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.30 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5576782 | 0.93 | PTGS1 (0.35) | PTGS1PTGS2DRD2SLC6A3NRP1 | |
| SCHEMBL5577134 | 0.92 | PTGS1 (0.35) | PTGS1PTGS2DRD2SLC6A3NRP1 | |
| SCHEMBL5312226 | 0.91 | PTGS1 (0.36) | PTGS1PTGS2DRD2SLC6A3 | |
| SCHEMBL5310169 | 0.90 | PTGS1 (0.35) | PTGS1PTGS2DRD2SLC6A3 | |
| SCHEMBL5307810 | 0.87 | NRP1 (0.32) | DRD2SLC6A3NRP1 | |
| SCHEMBL5308103 | 0.85 | PTGS1 (0.36) | PTGS1PTGS2P2RX4PTGES2 | |
| SCHEMBL5307952 | 0.85 | PTGS1 (0.36) | PTGS1PTGS2P2RX4PTGES2 | |
| Hydrochloric Acid SCHEMBL5310493 | 0.85 | PTGS1 (0.36) | PTGS1PTGS2P2RX4PTGES2 | |
| Bromide SCHEMBL5576990 | 0.85 | PTGS1 (0.36) | PTGS1PTGS2P2RX4PTGES2 | |
| Hydrochloric Acid SCHEMBL5311251 | 0.84 | PTGS1 (0.35) | PTGS1PTGS2P2RX4PTGES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007052831-A1 | PREVENTIVES/REMEDIES FOR URINARY DISTURBANCE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-05-10 | — | — | WO | disclosed |
| WO-2007052831-A1 | PREVENTIVES/REMEDIES FOR URINARY DISTURBANCE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-05-10 | — | — | WO | disclosed |
| US-20070099986-A1 | Preventives/remedies for urinary disturbance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-05-03 | — | — | US | disclosed |
| US-20070099986-A1 | Preventives/remedies for urinary disturbance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-05-03 | — | — | US | disclosed |
| US-20070099986-A1 | Preventives/remedies for urinary disturbance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070099986-A1 | Preventives/remedies for urinary disturbance | REN, GLS, ATP6V1B1 | PTGS1 344/4885PTGS2 638/4885DRD2 1113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.